A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

Summary

Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)

Timeline

Start

2009-04

Primary completion

2010-07

Completion

2010-07

Outcome

Missed primary endpoint

Stopped: “See termination reason in detailed description.”

registry analysis (superiority or other test); Placebo vs PF-00489791 1 mg; p = 0.120; Predicted Mean Difference -115.0 (95% CI -371.5 to -1.1); Bayesian 4-parameter Emax model NCT00853112 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-00489791	Small molecule	1 mg	Oral
Subject	PF-00489791	Small molecule	2 mg	Oral
Subject	PF-00489791	Small molecule	4 mg	Oral
Subject	PF-00489791	Small molecule	10 mg	Oral
Subject	PF-00489791	Small molecule	20 mg	Oral
Comparator	Sildenafil	Unknown	20 mg	—

Indications